Why "humans implanted" is the honest scoreboard
Demos and valuations are easy to inflate; people living with an implant are not. The count of humans implanted is the hardest signal that a BCI has crossed from lab to clinic — and Synchron, not the loudest name, leads it.
Brain-computer interfaces generate spectacular demos — a paralyzed person moving a cursor, typing, or playing chess by thought. Demos are necessary, but they are also the easiest thing to stage. The number that resists hype is how many real people are living with a given implant, day after day, outside a single highlight reel.
That count reorders the field in a useful way. Neuralink draws the most attention and the highest valuation, with five recipients of its 1,024-electrode N1. But by recipient count the leader is Synchron, whose less invasive Stentrode has been implanted in ten people across the US and Australia — a direct consequence of a device that does not require open-brain surgery. Paradromics joined the human stage in 2025, and Precision's FDA clearance opens a clinical path of its own.
None of this settles which approach ultimately wins; a higher-bandwidth implant in five people may yet matter more than a simpler one in ten. But patients implanted is the metric hardest to fake and closest to the question that matters — has this technology actually reached people? — which is why the tracker leads with it.